Michael Kwiat, MD
Psychiatry · Beaver, PANPI 1366491094
Payments from drug & device makers
Across 1,241 payments — averaging $314.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$130K
- Acadia Pharmaceuticals Inc$97K
- Otsuka America Pharmaceutical, Inc.$89K
- Avanir Pharmaceuticals, Inc.$59K
- E.r. Squibb & Sons, L.L.C.$4K
- Axsome Therapeutics, Inc.$3K
- plus $10K from 21 others
What the payments were for
- Consulting fees$34,2519%
- Speaking & faculty fees$276,24571%
- Travel & lodging$55,57214%
- Food & beverage$23,9496%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 189 | $129,628 |
| Acadia Pharmaceuticals Inc | 218 | $96,631 |
| Otsuka America Pharmaceutical, Inc. | 215 | $89,085 |
| Avanir Pharmaceuticals, Inc. | 109 | $58,724 |
| E.r. Squibb & Sons, L.L.C. | 13 | $3,804 |
| Axsome Therapeutics, Inc. | 41 | $2,745 |
| AbbVie(2 entities) | 97 | $1,783 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $1,241 |
| Alkermes, Inc. | 47 | $1,181 |
| Teva Pharmaceuticals USA, Inc. | 41 | $1,004 |
| Takeda Pharmaceuticals U.S.A., Inc. | 71 | $973 |
| Lundbeck LLC | 47 | $887 |
| Johnson & Johnson | 21 | $699 |
| Bausch Health US, LLC | 22 | $415 |
| Vanda Pharmaceuticals Inc. | 13 | $315 |
| Idorsia Pharmaceuticals US Inc | 12 | $222 |
| Almatica Pharma LLC | 11 | $218 |
| Sage Therapeutics, LLC | 8 | $163 |
| Indivior Inc. | 7 | $149 |
| Biogen | 7 | $118 |
| Sun Pharmaceutical Industries Inc. | 5 | $88 |
| Eisai Inc. | 5 | $71 |
| Alfasigma USA, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| UCB, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$126,706
- NUPLAZID$92,786
- NUEDEXTA$57,381
- REXULTI$54,639
- ABILIFY MAINTENA$31,337
- ABILIFY ASIMTUFII$17,239
- COBENFY$3,540
- Auvelity$2,067
- LYBALVI$876
- ARISTADA$475
- CAPLYTA$369
- SPRAVATO$244
- VRAYLAR$217
- ARISTADA INITIO$119
- Fanapt$111
How this compares
$390,256 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 133 | $756,605 |
| RexultiBrexpiprazole | 260 | $256,363 |
| Abilify MaintenaAripiprazole | 70 | $206,528 |
| NuplazidPimavanserin Tartrate | 28 | $123,749 |
| Austedo XrDeutetrabenazine | 14 | $119,833 |
| VraylarCariprazine Hcl | 60 | $98,757 |
| TrintellixVortioxetine Hydrobromide | 92 | $50,368 |
| AristadaAripiprazole Lauroxil | 12 | $41,538 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,748 |
| AuvelityDextromethorphan Hbr/Bupropion | 28 | $23,246 |
| Duloxetine Hcl | 731 | $18,374 |
| Divalproex Sodium | 504 | $16,329 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $14,730 |
| Aripiprazole | 198 | $9,879 |
| Chlorpromazine Hcl | 27 | $8,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $129,628 | $756,605133 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $89,085 | $462,891330 claims |
| Acadia Pharmaceuticals IncNuplazid | $96,631 | $123,74928 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,004 | $119,83314 claims |
| AbbVieVraylar | $1,783 | $98,75760 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $973 | $50,36892 claims |
| Alkermes, Inc.Aristada | $1,181 | $41,53812 claims |
| Johnson & JohnsonInvega Sustenna | $699 | $38,74811 claims |
| Axsome Therapeutics, Inc.Auvelity | $2,745 | $23,24628 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $58,724 | $14,73018 claims |
| Almatica Pharma LLCSertraline Hcl | $218 | $1,291106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Beaver
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.